RxSight
Stock Forecast, Prediction & Price Target
RxSight (RXST) stock Price Target by analysts
$71
Potential upside: 725.58%
RxSight price prediction
What is RxSight stock analysts` prediction?
RxSight stock forecast: Based on 6 Wall Street analysts` predicted price targets for RxSight in the last 3 months, the avarage price target is $71, with a high forecast of $NaN. The average price target represents a 725.58% change from the last price of $8.6.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
RxSight stock Price Target by analysts
Full breakdown of analysts given RxSight price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Curry Baker Guggenheim | 0% 0/1 | 10 months ago | $52 504.65% upside | $52 | Benzinga | Previous targets (0) |
Adam Seiden Barclays | 0% 0/1 | 10 months ago | $110 1179.06% upside | $52 | Benzinga | Previous targets (0) |
Anthony Crowdell Mizuho Securities | 0% 0/1 | 10 months ago | $67 679.06% upside | $52 | Benzinga | Previous targets (0) |
Young Li Jefferies | 0% 0/1 | 10 months ago | $72 737.20% upside | $50.25 | StreetInsider | Previous targets (0) |
Ryan Zimmerman BTIG | 0% 0/2 | 12 months ago | $59 586.04% upside | $52.98 | StreetInsider | Previous targets (1) |
David Saxon Needham | 25% 1/4 | 12 months ago | $66 667.44% upside | $54.54 | StreetInsider | Previous targets (3) |
David Saxon Needham | 25% 1/4 | about 1 year ago | $54 527.90% upside | $47.15 | StreetInsider | Previous targets (3) |
Thomas Stephan Stifel Nicolaus | 0% 0/2 | about 1 year ago | $65 655.81% upside | $40.78 | Benzinga | Previous targets (1) |
Lawrence Biegelsen Wells Fargo | 50% 1/2 | over 1 year ago | $68 690.69% upside | $62.84 | StreetInsider | Previous targets (1) |
David Saxon Needham | 25% 1/4 | over 1 year ago | $75 772.09% upside | $62.84 | StreetInsider | Previous targets (3) |
Ryan Zimmerman BTIG | 0% 0/2 | over 1 year ago | $72 737.20% upside | $62.84 | StreetInsider | Previous targets (1) |
Tom Stephan Stifel Nicolaus | 0% 0/1 | over 1 year ago | $75 772.09% upside | $62.84 | StreetInsider | Previous targets (0) |
Steven Lichtman Oppenheimer | 0% 0/1 | over 1 year ago | $72 737.20% upside | $62.84 | StreetInsider | Previous targets (0) |
Thomas Stephan Stifel Nicolaus | 0% 0/2 | over 1 year ago | $68 690.69% upside | $61.68 | TheFly | Previous targets (1) |
Lawrence Biegelsen Wells Fargo | 50% 1/2 | over 1 year ago | $42 388.37% upside | $39.78 | StreetInsider | Previous targets (1) |
David Saxon Needham | 25% 1/4 | about 2 years ago | $34 295.34% upside | $30.86 | Benzinga | Previous targets (3) |
RxSight Financial Estimates
RxSight Revenue Estimates
RxSight EBITDA Estimates
RxSight Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $22.59M N/A | $49.00M 116.90% | $89.07M 81.77% | Avg: $180.87M Low: $168.64M High: $193.21M avg. 103.05% | Avg: $221.80M Low: $212.80M High: $231.15M avg. 22.62% | Avg: $254.5M Low: $244.18M High: $265.22M avg. 14.74% | Avg: $288.6M Low: $276.89M High: $300.76M avg. 13.39% |
Net Income
% change YoY
| $-48.68M N/A | $-66.75M -37.10% | $-48.60M 27.18% | Avg: $-18.87M Low: $-25.49M High: $-10.68M avg. 61.17% | Avg: $-9.64M Low: $-21.01M High: $2.06M avg. 48.87% | Avg: $-4.82M Low: $-5.08M High: $-4.56M avg. 50.00% | Avg: $-9.30M Low: $-9.81M High: $-8.81M avg. -92.85% |
EBITDA
% change YoY
| $-52.73M N/A | $-61.80M -17.19% | $-41.03M 33.59% | Avg: $-163.31M Low: $-174.46M High: $-152.27M avg. -297.97% | Avg: $-200.27M Low: $-208.71M High: $-192.14M avg. -22.62% | Avg: $-229.79M Low: $-239.48M High: $-220.47M avg. -14.74% | Avg: $-260.58M Low: $-271.56M High: $-250.01M avg. -13.39% |
EPS
% change YoY
| -$1.78 N/A | -$2.41 -35.39% | -$1.41 41.49% | Avg: -$0.5 Low: -$0.74 High: -$0.31 avg. 64.8% | Avg: -$0.25 Low: -$0.61 High: $0.06 avg. 50.46% | Avg: -$0.14 Low: -$0.15 High: -$0.13 avg. 43.05% | Avg: -$0.27 Low: -$0.28 High: -$0.26 avg. -92.85% |
Operating Expenses
% change YoY
| $57.30M N/A | $84.64M 47.71% | $103.85M 22.68% | Avg: $409.02M Low: $381.37M High: $436.93M avg. 293.85% | Avg: $501.57M Low: $481.23M High: $522.71M avg. 22.62% | Avg: $575.51M Low: $552.17M High: $599.77M avg. 14.74% | Avg: $652.62M Low: $626.16M High: $680.13M avg. 13.39% |
FAQ
What is RxSight stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.79% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -25.49M, average is -18.87M and high is -10.68M.
What is RxSight stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 38.45% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $168.64M, average is $180.87M and high is $193.21M.
What is RxSight stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 16.36% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$0.74, average is -$0.5 and high is $-0.31.
What is the best performing analyst?
In the last twelve months 6 analysts have been covering RxSight stock. The most successful analyst is Curry Baker.